Holli Loomans-Kropp, Ph.D., M.P.H.

Holli Loomans-Kropp, Ph.D., M.P.H.
Division of Cancer Prevention (DCP)
Entry Year

Doctoral Degree

Ph.D., Cancer Biology, Vanderbilt University (2017)

Master's Degree

M.P.H., University of Texas-Houston (2012)

Research Interests

Biomarkers; Early Detection; Epidemiology-Biology Bridge; Gastrointestinal Cancers; Translational Research

Primary Preceptor/Branch

Asad Umar, D.V.M., Ph.D., Gastrointestinal and Other Cancers Branch (GCB), Division of Cancer Prevention (DCP)

Program Spotlight

Dr. Holli Loomans-Kropp selected to serve on the American Gastroenterological Association (AGA) Trainee and Early Career Committee for 2-year term

May 19, 2021

Dr. Holli Loomans-Kropp, a fourth-year Cancer Prevention Fellow working in the Gastrointestinal and Other Cancers Branch of the Division of Cancer Prevention, has been appointed to serve on the American Gastroenterological Association (AGA) Trainee and Early Career Committee. The AGA Trainee and Early Career Committee is a 12-member committee that works to enhance the value of AGA membership and career development opportunities for early-career GI scientists. Dr. Loomans-Kropp will occupy the sole seat on the committee reserved for a postdoctoral fellow for a two-year term that formally begins in June 2021.

It was while researching additional leadership and training opportunities outside of NIH that Dr. Loomans-Kropp came across the AGA Trainee and Early Career Committee and decided to apply. She had been participating in other AGA-sponsored activities and events (e.g., Digestive Disease Week) since her graduate school days training in cancer biology at Vanderbilt and found this Committee’s responsibilities especially appealing. Having held positions related to career development, she is excited to be contributing to the “development of educational programs that will be useful to trainees during their fellowship”, in addition to “working with other committees within AGA to better serve the training needs of early-career members.” Personally, she is hoping to gain additional collaborative and leadership skills, as well as build a diverse network of colleagues in similar fields.

Dr. Loomans-Kropp became a member of the AGA in 2017 – the same year that she entered the CPFP. She stated that this international association, founded in 1897, is “a great organization that bridges gastroenterological clinical work and research. Because of my interest in translational research, AGA provides a prime opportunity to stay on top of the advances in gastroenterology, particularly gastrointestinal cancers.” And, for those fellows whose interests lie in gastrointestinal diseases and cancer, she recommends the AGA as “a great way to stay in the know of the hot topics and clinical trials in the field."

Holli Loomans-Kropp, Ph.D, M.P.H.
Current Fellow, 2017 CPFP Cohort

Dr. Loomans-Kropp, Dr. Pierre-Victor, with Division of Cancer Prevention Mentors, Publish on Personalized Risk

April 5, 2019

Current CPFP fellow Dr. Holli Loomans-Kropp, recently published a review in Precision Oncology titled “Cancer prevention and screening: the next step in the era of precision medicine.” In this piece, Loomans-Kropp and her Division of Cancer Prevention (DCP) preceptor and Chief of the Gastrointestinal and Other Cancers Research Group, Dr. Asad Umar, summarized the current state of cancer prevention efforts along the cancer control continuum. They discussed historical efforts in prevention, current prevention and early detection recommendations, and current knowledge of the molecular factors that may impact one’s risk of cancer. The review also explored the future of cancer prevention in the current age of precision medicine and personalized care.

Loomans-Kropp and Umar highlighted the necessity of combining generalized cancer prevention techniques with individualized methods. Loomans-Kropp noted, “Better understanding one’s personalized risk of one, or multiple, cancers may better inform how she or he should approach cancer prevention. This type of knowledge will allow for better and more precise guidance in cancer prevention.”

In February 2019, current CPFP fellow Dr. Dudith Pierre-Victor, with mentor and Chief of DCP’s Early Detection Research Branch Dr. Paul Pinsky, published a study in JAMA Internal Medicine. The study, titled “Association of Nonadherence to Cancer Screening Examinations with Mortality from Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial” examined the association between nonadherence to cancer screening tests and mortality in the Prostate, Lung, Colorectal Ovarian Cancer Screening Trial (PLCO), excluding mortality from cancer studied in the trial. Pierre-Victor and Pinsky observed higher mortality among participants who were nonadherent to baseline cancer screening tests compared to those who fully adhered. A general behavior profile of nonadherence, of which nonadherence specifically with trial protocol screening is a marker, was found to be associated with a very substantial increased risk of death.

Dr. Pierre-Victor stressed the impact of this study on middle-aged and older populations: “Study participants’ adherence profile is a behavioral characteristic that merits investigation since it is associated with an increased risk of mortality among middle-aged and older adults.”

Holli Loomans-Kropp, Ph.D., M.P.H.
Current Fellow, 2017 CPFP Cohort